Aclarion Inc (ACON) Stock Price, Quote & News

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning inter...

Industry: Health Information Services

Sector: Healthcare

Phone: 833 275 2266

Website: www.aclarion.com

Address:

8181 Arista Place, Suite 100, Broomfield, United States

SA449 Jun. 24 at 9:40 PM

$ACON " TO THE TOP "🚀📈🪙🤑

1 · Reply

TraderJames2323 Jun. 24 at 9:36 PM

$ACON

0 · Reply

PatentGrants Jun. 24 at 7:56 PM

$ACON Aclarion has received a Notice of Allowance for a US patent titled "MULTI-VOXEL PRESCRIPTION FOR LUMBAR DISC EVALUATION". https://patentcenter.uspto.gov/applications/18917748/ifw/docs

0 · Reply

WindMan20 Jun. 24 at 7:28 PM

$ACON just give me that 4$, they offered. I'll accept my loss

0 · Reply

TraderJames2323 Jun. 24 at 5:31 PM

$LMFA $ACON - 🚀

0 · Reply

TraderJames2323 Jun. 24 at 10:48 AM

$ACON

0 · Reply

brightgreen68 Jun. 22 at 9:23 PM

$ACON the board quiely issue hundred thousands of new shares to themself, and refuse buyout at 4. What a corrupt management

0 · Reply

TraderJames2323 Jun. 22 at 5:22 PM

$ACON 180k Shares Short, almost 10% of the float.. This screams a short squeeze... $6+ in cash per share..

0 · Reply

TraderJames2323 Jun. 22 at 2:58 PM

$ACON

0 · Reply

GoldmanSlaps Jun. 22 at 4:45 AM

$ACON on watch they got a take over offer for 4 CO said too cheap

0 · Reply

Aclarion Transcript: Planet MicroCap Las Vegas 2026

2026-06-09T13:24:57.000Z - 15 days ago

Aclarion partners with PRIA Healthcare to expand access to Nociscan

2026-06-08T11:28:03.000Z - 16 days ago

Aclarion rejects Echo Lake acquisition proposal

2026-05-28T18:55:11.000Z - 27 days ago

Aclarion to ‘carefully review and evaluate’ Echo Lake’s proposal

2026-05-28T12:38:18.000Z - 27 days ago

Echo Lake offers to acquire Aclarion for $4 per share in cash

May 28, 2026, 8:00 AM EDT - 27 days ago

Echo Lake Capital Offers To Acquire Aclarion Inc.

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Aclarion Quarterly report: Q1 2026

2026-05-05T11:37:11.000Z - 7 weeks ago

Aclarion enters second commercial agreement with Weill Cornell Medicine

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Aclarion Proxy statement: Proxy filing

2026-04-22T13:10:35.000Z - 2 months ago

Aclarion announces $2.5M share repurchase program

2026-04-16T10:52:45.000Z - 2 months ago

Aclarion granted U.S. patent for AI-driven back pain assessment

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Aclarion Receives Pinnacle Award for AI Innovation

2026-04-08T12:21:37.000Z - 2 months ago

Aclarion announces commercial agreement with Weill Cornell Medicine

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Aclarion Proxy statement: Proxy filing

2026-03-24T12:25:45.000Z - 3 months ago

Echo Lake calls on Aclarion director David Neal to resign

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.

2026-03-19T13:37:04.000Z - 3 months ago

Aclarion adopts limited duration stockholder rights plan

2026-03-19T10:11:08.000Z - 3 months ago

Aclarion’s CEO publishes shareholder letter

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Aclarion Annual report: Q4 2025

2026-01-13T11:11:19.000Z - 5 months ago

Aclarion strengthens balance sheet, extends cash runway into 2028

2026-01-08T15:05:25.000Z - 5 months ago

Aclarion Inc trading resumes

2026-01-08T15:00:34.000Z - 5 months ago

Aclarion Inc trading halted, volatility trading pause

2026-01-08T13:03:55.000Z - 5 months ago

Why Is Aclarion Stock (ACON) Up Today?

2026-01-06T11:20:12.000Z - 6 months ago

Aclarion says first patients enrolled at two additional CLARITY trial sites

2025-12-04T13:15:42.000Z - 7 months ago

Aclarion announces publication of Nociscan article in pain issue of IJSS

2025-12-02T13:10:19.000Z - 7 months ago

Aclarion appoints Jason Brosniak as commercial director, Eastern U.S.

Dec 2, 2025, 8:00 AM EST - 7 months ago

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Nov 12, 2025, 7:00 AM EST - 8 months ago

Aclarion Quarterly report: Q3 2025

Oct 22, 2025, 6:00 AM EDT - 8 months ago

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 20, 2025, 3:00 PM EDT - 8 months ago

Aclarion Transcript: LD Micro Main Event XIX Investor Conference

Oct 9, 2025, 6:00 AM EDT - 9 months ago

Aclarion to Present at the LD Micro Main Event XIX

2025-10-01T11:25:06.000Z - 9 months ago

Aclarion presents on Nociscan technology at LSI Europe ’25

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Aclarion Quarterly report: Q2 2025

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

May 20, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 14, 2025, 6:00 PM EDT - 1 year ago

Aclarion Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

May 12, 2025, 7:34 AM EDT - 1 year ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

May 2, 2025, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Aclarion Slides: Corporate Presentation

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Aclarion Registration statement: Registration Filing

Apr 23, 2025, 12:00 PM EDT - 1 year ago

Aclarion Transcript: Planet MicroCap Showcase VEGAS 2025

Apr 23, 2025, 6:00 AM EDT - 1 year ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 8, 2025, 6:00 PM EDT - 1 year ago

Aclarion Annual report: Q4 2024

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 13, 2025, 9:25 AM EDT - 1 year ago

Aclarion Provides Shareholder Update

Mar 6, 2025, 9:35 AM EST - 1 year ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 3, 2025, 6:00 AM EST - 1 year ago

Aclarion Announces First Commercial Agreement with Scripps Health

Feb 28, 2025, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Feb 20, 2025, 6:00 PM EST - 1 year ago

Aclarion Slides: Corporate Presentation

Feb 20, 2025, 6:00 AM EST - 1 year ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 11, 2025, 7:58 AM EST - 1 year ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 6, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 4, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Feb 3, 2025, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Jan 22, 2025, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Dec 26, 2024, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Dec 11, 2024, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Dec 2, 2024, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Nov 23, 2024, 7:00 AM EST - 1 year ago

Aclarion Transcript: Investor Update

Nov 22, 2024, 7:00 AM EST - 1 year ago

Aclarion Proxy statement: Proxy Filing

Nov 21, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 14, 2024, 5:00 PM EST - 1 year ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Nov 13, 2024, 6:00 PM EST - 1 year ago

Aclarion Quarterly report: Q3 2024

Nov 4, 2024, 7:00 AM EST - 1 year ago

Aclarion Registration statement: Registration Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Aclarion Registration statement: Registration Filing

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 6:57 AM EDT - 1 year ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Aclarion Registration statement: Registration Filing

Sep 13, 2024, 8:30 AM EDT - 1 year ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 12, 2024, 6:57 AM EDT - 1 year ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 10, 2024, 6:57 AM EDT - 1 year ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Aclarion Registration statement: Registration Filing

Sep 5, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aug 29, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Aclarion Proxy statement: Proxy Filing

Aug 21, 2024, 7:57 AM EDT - 2 years ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 20, 2024, 4:00 AM EDT - 2 years ago

Aclarion Transcript: Investor Update

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Aclarion Proxy statement: Proxy Filing

Aug 15, 2024, 9:48 AM EDT - 2 years ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 8:08 AM EDT - 2 years ago

Aclarion Announces First Commercial Agreement in Michigan

Aug 13, 2024, 6:00 PM EDT - 2 years ago

Aclarion Quarterly report: Q2 2024

Aug 13, 2024, 9:07 AM EDT - 2 years ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 25, 2024, 8:30 AM EDT - 2 years ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

May 14, 2024, 6:00 PM EDT - 2 years ago

Aclarion Quarterly report: Q1 2024

Apr 25, 2024, 9:14 AM EDT - 2 years ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Mar 27, 2024, 7:00 PM EDT - 2 years ago

Aclarion Annual report: Q4 2023

Feb 27, 2024, 3:22 PM EST - 2 years ago

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 2 years ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 23, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Feb 21, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Feb 6, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Feb 5, 2024, 8:00 AM EST - 2 years ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Jan 31, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Jan 22, 2024, 8:00 AM EST - 2 years ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Jan 22, 2024, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Dec 11, 2023, 7:00 AM EST - 2 years ago

Aclarion Registration statement: Registration Filing

Nov 27, 2023, 8:00 AM EST - 2 years ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 13, 2023, 6:00 PM EST - 2 years ago

Aclarion Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Aclarion Proxy statement: Proxy Filing

Nov 6, 2023, 8:00 AM EST - 2 years ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Aclarion Proxy statement: Proxy Filing

Oct 25, 2023, 8:30 AM EDT - 2 years ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 24, 2023, 8:45 AM EDT - 2 years ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Aclarion Registration statement: Registration Filing

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Aclarion Registration statement: Registration Filing

Aug 25, 2023, 4:10 PM EDT - 3 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

SA449 Jun. 24 at 9:40 PM

$ACON " TO THE TOP "🚀📈🪙🤑

1 · Reply

TraderJames2323 Jun. 24 at 9:36 PM

$ACON

0 · Reply

PatentGrants Jun. 24 at 7:56 PM

$ACON Aclarion has received a Notice of Allowance for a US patent titled "MULTI-VOXEL PRESCRIPTION FOR LUMBAR DISC EVALUATION". https://patentcenter.uspto.gov/applications/18917748/ifw/docs

0 · Reply

WindMan20 Jun. 24 at 7:28 PM

$ACON just give me that 4$, they offered. I'll accept my loss

0 · Reply

TraderJames2323 Jun. 24 at 5:31 PM

$LMFA $ACON - 🚀

0 · Reply

TraderJames2323 Jun. 24 at 10:48 AM

$ACON

0 · Reply

brightgreen68 Jun. 22 at 9:23 PM

$ACON the board quiely issue hundred thousands of new shares to themself, and refuse buyout at 4. What a corrupt management

0 · Reply

TraderJames2323 Jun. 22 at 5:22 PM

$ACON 180k Shares Short, almost 10% of the float.. This screams a short squeeze... $6+ in cash per share..

0 · Reply

TraderJames2323 Jun. 22 at 2:58 PM

$ACON

0 · Reply

GoldmanSlaps Jun. 22 at 4:45 AM

$ACON on watch they got a take over offer for 4 CO said too cheap

0 · Reply

JLCw Jun. 19 at 9:36 PM

FINAL WATCHLIST $GPUS AI + crypto + robotics, needs 0.95 break $NXGL slow grind turnaround, needs confirmation $PULM merger story, timing-dependent $ACON fundamentals are strong, but need volume Have a great long weekend and happy Father's Day! - JL

1 · Reply

SA449 Jun. 18 at 9:18 PM

$ACON TO THE TOP 🚀📈

1 · Reply

SA449 Jun. 18 at 3:36 PM

$ACON

0 · Reply

TraderJames2323 Jun. 18 at 1:46 PM

$ACON

0 · Reply

SA449 Jun. 17 at 8:53 PM

$ACON " TO THE TOP " Extremely Bullish 🚀🗻🪙💰🤑